eligibility_summary
Inclusion: adults ≥18 with relapsed/progressive SCLC after 1 platinum regimen, measurable disease, ECOG 0–1, ≥12 wk life expectancy, adequate organ function. Exclusion: symptomatic CNS or leptomeningeal disease, prior severe ICI toxicity, active autoimmune disease/immunosuppression, transplant, recent other cancer, MI/CHF>II or stroke/TIA ≤12 mo, active viral/bacterial infection, ILD/pneumonitis. No prior tarlatamab/DLL3 or >1 line, washouts (therapy, CYP3A/P‑gp/BCRP), no recent surgery/vaccines, no other trials, pregnancy/contraception limits.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05740566: Randomized, open-label Phase 3 in relapsed SCLC after platinum. Interventions: 1) Tarlatamab (AMG 757) – immunotherapy, a half-life–extended bispecific T-cell engager antibody that binds DLL3 on SCLC cells and CD3 on T cells to redirect cytotoxic T-cell killing. 2) Standard chemotherapy options: Lurbinectedin – DNA-binding alkylating/transcription inhibitor that suppresses RNA Pol II, causing DNA damage, Topotecan – camptothecin analog, topoisomerase I inhibitor causing DNA strand breaks, Amrubicin – anthracycline, active metabolite inhibits topoisomerase II and intercalates DNA. Targets/pathways: DLL3 (Notch ligand) on tumor, CD3/TCR on T cells, DNA transcription (Pol II), and DNA topology via TOP1/TOP2.